. In general, albuterol was a superior bronchodilator to theophylline and albuterol alone was equivalent to albuterol combined with theophylline. Filuk and colleagues,22 in contrast, could identify two classes of patients with COPD: responders and nonresponders. In a study of 13 patients, all of whom had COPD, short-term improvements in airflow were assessed following the sequential administration of albuterol or theophylline 90 min apart. Nonresponders had no improvement in airflow following either drug. Responders, in contrast, had improvement in airflow following the administration of both bronchodilators when used as the initial therapeutic agent and had further bronchodilation when given the second drug. Interestingly, the additive benefit of a second bronchodilator seemed to be superior when theophylline was given prior to administration of albuterol, suggesting that a sequential effect may be important. Thus. it is possible that studies not demonstrating a benefit of theophylline combined with a /-agonist may have included a number of "nonresponders" or may have failed to reveal acute effects because of the importance of a sequential effect.
While the subject remains controversial, many prominent pulmonologists continue to believe that combined therapy is important.1'2'23'24 Snider,24 for example, has summarized clinical approaches: "Because theophylline has a different mode of action, it continues to have a useful place in the ambulatory management of chronic obstructive pulmonary disease.
While the utility of this combination may well depend on improvements in airflow as assessed by FEVy, it is important to remember that both agents 172S can have a variety of other beneficial effects. Thus, clinical benefits may exceed apparent improvements in FEV1. Taylor and colleagues,12 for example, studied 25 patients with chronic bronchitis using a double crossover design similar to that used by Tandon and Kailis.1" While they found that the combination resulted in superior FEV, to either drug alone or to the placebo, the benefits were very small, 7% improvement for the combination compared with 4% for theophylline and 2% for albuterol used alone. When the patients, however, rated their own response to the various drugs, more than 50% ranked the combination as the best therapy while more than 50% ranked the double placebo as the worst. Thus, while the precise modes of action remain to be fully delineated, the weight of clinical evidence would, at present, seem to support the use of ,B-agonists and theophylline in combination in patients with COPD both because of improved airflow as assessed by FEVI and by improved symptoms.
ANTICHOLINERGICS
The third major class of bronchodilator currently available for use in COPD is anticholinergic drugs.8'9'25 These drugs are thought to inhibit the action of acetylcholine released at cholinergic nerve endings on smooth muscle which, through actions on the M3 muscarinic receptor on smooth muscle, lead to smooth muscle contraction. It is important to note that currently available anticholinergics are not selective and can inhibit other classes of muscarinic receptor. Anticholinergics, therefore, can reduce "cholinergic tone" in the airways and improve airflow. Because d-agonists are thought to directly induce bronchodilatation, it has been suggested that a maximal degree of bronchodilatation can be achieved, and that a single drug used to maximum effect can induce all possible improvements in airflow. Several studies would seem to support this argument.2628 Karpel and colleagues,29'30 for example, administered either the ,B-agonist albuterol or the anticholinergic ipratropium and followed airflow short term. Thirty minutes after the first drug, the alternative drug was added. In 32 patients with COPD in acute exacerbation, both drugs resulted in a significant improvement in airflow short term. Addition of a second drug resulted in no further bronchodilatation. Thirty subjects were restudied several weeks following the acute exacerbation, and a similar effect was observed: both drugs caused initial bronchodilatation, but addition of a second drug had no additional effect. Interestingly, when the patients were in stable condition, airflow was considerably better than the "maximum" obtained during the exacerbation, suggesting that "maximal airflow" in A recent double-blinded, parallel, placebo-controlled study assessed the hypothesis that ipratropium bromide solution added to albuterol increases bronchodilatation over a 90-day period.45 One group received ipratropium bromide, 500 ,g added to albuterol, 2.5 mg, administered via a nebulized solution. The second group received a placebo added to 2.5 mg of albuterol administered by the same route. All subjects had to be smokers (210 pack-years) or ex-smokers, over age 40 years, and have stable COPD with an FEV, <65% of predicted and an FEVI/FVC ratio <75%. Asthma, significant complicating medical illnesses, recent upper respiratory tract infections, and any problems that might put participants at risk with the administration of anticholinergics were exclusionary criteria. Albuterol administered alone resulted in a significant improvement in FEV, and in forced vital capacity. Ipratropium, when added in combination with albuterol, resulted in improved maximal airflow, and the improvement in airflow was more long lasting. These benefits of the combination over albuterol alone were observed both on the first day of the trial and after 90 days.
OTHER DRUGS AND BRONCHODILATION
Drugs other than direct bronchodilators can also have significant effects on airflow. Inflammation of the airway, for example, is thought to play an important role in chronic bronchitis. By causing tissue edema and by distorting tissue architecture through the infiltration of inflammatory cells, inflammatory processes can alter airway architecture. Not only is airflow dependent on airway structure, but the effects of bronchodilatation greatly depend on airway diameter: smaller airways are much more sensitive to bronchoconstriction than are larger ones. 46 Thus, in the face of edema or inflammation, a relatively small degree of bronchoconstriction can have an increased effect in reducing airflow. Conversely, an agent that reduces airway inflammation can augment the effects of bronchodilators. In this regard, most studies have found that glucocorticoids, while not direct bronchodilators, improve airflow in a number of patients when administered by both inhaled47,48 and systemic routes.49-52 However, this has not been a universal finding,53 and patient selection may be critical.52 The effects of glucocorticoids on airflow, as would be expected from an effect on inflammation, develop more slowly than direct bronchodilators. It is, as yet, unclear how long a clinical trial of glucocorticoids is required to determine if a given patient will benefit from such therapy.50 '54,55 In current practice, a trial of several weeks is recommended as a minimum.1'2 One current strategy is to administer 0.5 to 1 mg prednisone or equivalent orally each morning for 2 to 3 weeks. Improvement in FEV, of 20 to 25% compared with baseline should be regarded as a positive response.
The long-term benefits of glucocorticoids administered together with bronchodilators in patients with COPD are not completely understood. In one study, Dompeling and colleagues56 noted that beclomethasone added to a regimen of bronchodilators resulted in improved lung functioning. When followed up over a period of 2 years, however, subjects with COPD treated with beclomethasone continued to demonstrate a decline in lung function at the same rate as that prior to beclomethasone, although their decline was occurring from an improved level. Thus, current data would certainly support the addition of glucocorticoids in combination with bronchodilators to improve airflow at least in selected individuals. 
